Clonidine	clonidine	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
attention-deficit/hyperactivity	attention-deficit/hyperactivity	O	O	O	O
disorder	disorder	O	O	O	O
:	:	O	O	O	O
II	ii	O	O	O	O
.	.	O	O	O	O

ECG	ecg	O	O	O	O
changes	changes	O	O	O	O
and	and	O	O	O	O
adverse	adverse	O	O	O	O
events	events	O	O	O	O
analysis	analysis	O	O	O	O
.	.	O	O	O	O

OBJECTIVE	objective	O	O	O	O
:	:	O	O	O	O
To	to	O	O	O	O
examine	examine	O	O	O	O
the	the	O	O	O	O
safety	safety	O	O	O	O
and	and	O	O	O	O
tolerability	tolerability	O	O	O	O
of	of	O	O	O	O
clonidine	clonidine	CHEMICALS	O	OTHERS	I
used	used	O	O	O	O
alone	alone	O	O	O	O
or	or	O	O	O	O
with	with	O	O	O	O
methylphenidate	methylphenidate	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
children	children	O	O	O	O
with	with	O	O	O	O
attention-deficit/hyperactivity	attention-deficit/hyperactivity	O	O	O	O
disorder	disorder	O	O	O	O
(	(	O	O	O	O
ADHD	adhd	O	O	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

METHOD	method	O	O	O	O
:	:	O	O	O	O
In	in	O	O	O	O
a	a	O	O	O	O
16-week	16-week	O	O	O	O
multicenter	multicenter	O	O	O	O
,	,	O	O	O	O
double-blind	double-blind	O	O	O	O
trial	trial	O	O	O	O
,	,	O	O	O	O
122	122	O	O	O	O
children	children	O	O	O	O
with	with	O	O	O	O
ADHD	adhd	O	O	OTHERS	I
were	were	O	O	O	O
randomly	randomly	O	O	O	O
assigned	assigned	O	O	O	O
to	to	O	O	O	O
clonidine	clonidine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
31	31	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
methylphenidate	methylphenidate	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
29	29	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
clonidine	clonidine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
methylphenidate	methylphenidate	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
32	32	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
or	or	O	O	O	O
placebo	placebo	O	O	O	O
(	(	O	O	O	O
n	n	O	O	OTHERS	I
=	=	O	O	O	O
30	30	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Doses	doses	O	O	O	O
were	were	O	O	O	O
flexibly	flexibly	O	O	O	O
titrated	titrated	O	O	O	O
up	up	O	O	O	O
to	to	O	O	O	O
0.6	0.6	O	O	O	O
mg/day	mg/day	O	O	O	O
for	for	O	O	O	O
clonidine	clonidine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
60	60	O	O	O	O
mg/day	mg/day	O	O	O	O
for	for	O	O	O	O
methylphenidate	methylphenidate	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
both	both	O	O	O	O
with	with	O	O	O	O
divided	divided	O	O	O	O
dosing	dosing	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Groups	groups	O	O	O	O
were	were	O	O	O	O
compared	compared	O	O	O	O
regarding	regarding	O	O	O	O
adverse	adverse	O	O	O	O
events	events	O	O	O	O
and	and	O	O	O	O
changes	changes	O	O	O	O
from	from	O	O	O	O
baseline	baseline	O	O	O	O
to	to	O	O	O	O
week	week	O	O	O	O
16	16	O	O	O	O
in	in	O	O	O	O
electrocardiograms	electrocardiograms	O	O	O	O
and	and	O	O	O	O
vital	vital	O	O	O	O
signs	signs	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
There	there	O	O	O	O
were	were	O	O	O	O
more	more	O	O	O	O
incidents	incidents	O	O	O	O
of	of	O	O	O	O
bradycardia	bradycardia	O	DISEASE	OTHERS	I
in	in	O	O	O	O
subjects	subjects	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
clonidine	clonidine	CHEMICALS	O	OTHERS	I
compared	compared	O	O	O	O
with	with	O	O	O	O
those	those	O	O	O	O
not	not	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
clonidine	clonidine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
17.5	17.5	O	O	O	O
%	%	O	O	O	O
versus	versus	O	O	O	O
3.4	3.4	O	O	O	O
%	%	O	O	O	O
;	;	O	O	O	O
p	p	O	O	OTHERS	I
=	=	O	O	O	O
.02	.02	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
no	no	O	O	O	O
other	other	O	O	O	O
significant	significant	O	O	O	O
group	group	O	O	O	O
differences	differences	O	O	O	O
regarding	regarding	O	O	O	O
electrocardiogram	electrocardiogram	O	O	O	O
and	and	O	O	O	O
other	other	O	O	O	O
cardiovascular	cardiovascular	O	O	O	O
outcomes	outcomes	O	O	O	O
.	.	O	O	O	O

There	there	O	O	O	O
were	were	O	O	O	O
no	no	O	O	O	O
suggestions	suggestions	O	O	O	O
of	of	O	O	O	O
interactions	interactions	O	O	O	O
between	between	O	O	O	O
clonidine	clonidine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
methylphenidate	methylphenidate	CHEMICALS	O	OTHERS	I
regarding	regarding	O	O	O	O
cardiovascular	cardiovascular	O	O	O	O
outcomes	outcomes	O	O	O	O
.	.	O	O	O	O

Moderate	moderate	O	O	O	O
or	or	O	O	O	O
severe	severe	O	O	O	O
adverse	adverse	O	O	O	O
events	events	O	O	O	O
were	were	O	O	O	O
more	more	O	O	O	O
common	common	O	O	O	O
in	in	O	O	O	O
subjects	subjects	O	O	O	O
on	on	O	O	O	O
clonidine	clonidine	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
79.4	79.4	O	O	O	O
%	%	O	O	O	O
versus	versus	O	O	O	O
49.2	49.2	O	O	O	O
%	%	O	O	O	O
;	;	O	O	O	O
p	p	O	O	OTHERS	I
=	=	O	O	O	O
.0006	.0006	O	O	O	O
)	)	O	O	O	O
but	but	O	O	O	O
not	not	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
higher	higher	O	O	O	O
rates	rates	O	O	O	O
of	of	O	O	O	O
early	early	O	O	O	O
study	study	O	O	O	O
withdrawal	withdrawal	O	O	O	O
.	.	O	O	O	O

Drowsiness	drowsiness	O	O	OTHERS	I
was	was	O	O	O	O
common	common	O	O	O	O
on	on	O	O	O	O
clonidine	clonidine	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
but	but	O	O	O	O
generally	generally	O	O	O	O
resolved	resolved	O	O	O	O
by	by	O	O	O	O
6	6	O	O	O	O
to	to	O	O	O	O
8	8	O	O	O	O
weeks	weeks	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
Clonidine	clonidine	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
used	used	O	O	O	O
alone	alone	O	O	O	O
or	or	O	O	O	O
with	with	O	O	O	O
methylphenidate	methylphenidate	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
appears	appears	O	O	O	O
safe	safe	O	O	O	O
and	and	O	O	O	O
well	well	O	O	O	O
tolerated	tolerated	O	O	O	O
in	in	O	O	O	O
childhood	childhood	O	O	O	O
ADHD	adhd	O	O	OTHERS	I
.	.	O	O	O	O

Physicians	physicians	O	O	O	O
prescribing	prescribing	O	O	O	O
clonidine	clonidine	CHEMICALS	O	OTHERS	I
should	should	O	O	O	O
monitor	monitor	O	O	O	O
for	for	O	O	O	O
bradycardia	bradycardia	O	DISEASE	OTHERS	I
and	and	O	O	O	O
advise	advise	O	O	O	O
patients	patients	O	O	O	O
about	about	O	O	O	O
the	the	O	O	O	O
high	high	O	O	O	O
likelihood	likelihood	O	O	O	O
of	of	O	O	O	O
initial	initial	O	O	O	O
drowsiness	drowsiness	O	O	OTHERS	I
.	.	O	O	O	O

